Literature DB >> 7981053

Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay.

G J Kaspers1, A J Veerman, R Pieters, G J Broekema, D R Huismans, K M Kazemier, A H Loonen, M A Rottier, C H van Zantwijk, K Hählen.   

Abstract

The methyl-thiazol-tetrazolium (MTT) assay is a drug resistance assay which cannot discriminate between malignant and non-malignant cells. We previously reported that samples with > or = 80% leukaemic cells at the start of culture give similar results in the MTT assay and the differential staining cytotoxicity assay, in which a discrimination between malignant and non-malignant cells can be made. However, the percentage of leukaemic cells may change during culture, which might affect the results of the MTT assay. We studied 106 untreated childhood acute lymphoblastic leukemia (ALL) samples with > or = 80% leukaemic cells at the start of culture. This percentage decreased below 80% in 28%, and below 70% in 13%, of the samples after 4 days of culture. A decrease below 70% occurred more often in case of 80-89% leukaemic cells (9/29) than in case of > or = 90% leukaemic cells at the start of culture (5/77, P = 0.0009). Samples with < 70% leukaemic cells after culture were significantly more resistant to 6 out of 13 drugs, and showed a trend towards being more resistant to two more drugs, than samples with > or = 80% leukaemic cells. No such differences were seen between samples with 70-79% and samples with > or = 80% leukaemic cells after culture. We next studied in another 30 ALL samples whether contaminating mononuclear cells could be removed by using immunoamagnetic beads. Using a beads to target cell ratio of 10:1, the percentage of leukaemic cells increased from mean 72% (s.d. 9.3%) to mean 87% (s.d. 6.7%), with an absolute increase of 2-35%. The recovery of leukaemic cells was mean 82.1% (range 56-100%, s.d. 14.0%). The procedure itself did not influence the results of the MTT assay in three samples containing only leukaemic cells. We conclude that it is important to determine the percentage of leukaemic cells at the start and at the end of the MTT assay and similar drug resistance assays. Contaminating mononuclear cells can be successfully removed from ALL samples using immunomagnetic beads. This approach may increase the number of leukaemic samples which can be evaluated for cellular drug resistance with the MTT assay or a similar cell culture drug resistance assay.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981053      PMCID: PMC2033662          DOI: 10.1038/bjc.1994.446

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Interleukin-7 differentiates a subgroup of acute lymphoblastic leukemias.

Authors:  C Skjønsberg; B K Erikstein; E B Smeland; S O Lie; S Funderud; K Beiske; H K Blomhoff
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

2.  Model experiments for immunomagnetic elimination of leukemic cells from human bone marrow. Presentation of a novel magnetic separation system.

Authors:  B Gruhn; R Häfer; A Müller; W Andrä; H Danan; F Zintl
Journal:  Immunobiology       Date:  1991-11       Impact factor: 3.144

3.  Improved detection of allele loss in renal cell carcinomas after removal of leukocytes by immunologic selection.

Authors:  M Linehan; E Miller; P Anglard; M Merino; B Zbar
Journal:  J Natl Cancer Inst       Date:  1989-02-15       Impact factor: 13.506

4.  Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay.

Authors:  P R Twentyman; N E Fox; J K Rees
Journal:  Br J Haematol       Date:  1989-01       Impact factor: 6.998

5.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

Authors:  R Pieters; D R Huismans; A H Loonen; K Hählen; A van der Does-van den Berg; E R van Wering; A J Veerman
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

6.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

Authors:  R Pieters; A H Loonen; D R Huismans; G J Broekema; M W Dirven; M W Heyenbrok; K Hählen; A J Veerman
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

7.  Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.

Authors:  G J Kaspers; G Kardos; R Pieters; C H Van Zantwijk; E Klumper; K Hählen; F C de Waal; E R van Wering; A J Veerman
Journal:  Leukemia       Date:  1994-07       Impact factor: 11.528

8.  Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads.

Authors:  C Shimazaki; D Wisniewski; D A Scheinberg; J Atzpodien; A Strife; S Gulati; J Fried; R Wisniewolski; C Y Wang; B D Clarkson
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

Review 9.  Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays.

Authors:  L M Weisenthal; D H Kern
Journal:  Oncology (Williston Park)       Date:  1991-09       Impact factor: 2.990

10.  In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; P A De Laat; F C De Waal; E R Van Wering; A J Veerman
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

View more
  18 in total

1.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.

Authors:  Amy Holleman; Monique L den Boer; Renée X de Menezes; Meyling H Cheok; Cheng Cheng; Karin M Kazemier; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; William E Evans; Rob Pieters
Journal:  Blood       Date:  2005-09-27       Impact factor: 22.113

2.  Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Authors:  David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

3.  Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

Authors:  J A P Spijkers-Hagelstein; S S Pinhanços; P Schneider; R Pieters; R W Stam
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

4.  Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Martin Zimmermann; Justine K Peeters; Peter J M Valk; Brian V Balgobind; Edwin Sonneveld; Gertjan J L Kaspers; Eveline S J M de Bont; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

5.  Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols.

Authors:  Amy Holleman; Monique L den Boer; Meyling H Cheok; Karin M Kazemier; Deqing Pei; James R Downing; Gritta E Janka-Schaub; Ulrich Göbel; Ulrike B Graubner; Ching-Hon Pui; William E Evans; Rob Pieters
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

6.  MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.

Authors:  N S D Larmonie; T C J M Arentsen-Peters; A Obulkasim; D Valerio; E Sonneveld; A A Danen-van Oorschot; V de Haas; D Reinhardt; M Zimmermann; J Trka; A Baruchel; R Pieters; M M van den Heuvel-Eibrink; C M Zwaan; M Fornerod
Journal:  Oncogene       Date:  2017-09-11       Impact factor: 9.867

7.  Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.

Authors:  Esther Hulleman; Karin M Kazemier; Amy Holleman; David J VanderWeele; Charles M Rudin; Mathilde J C Broekhuis; William E Evans; Rob Pieters; Monique L Den Boer
Journal:  Blood       Date:  2008-10-31       Impact factor: 22.113

8.  miR-9 is a tumor suppressor in pediatric AML with t(8;21).

Authors:  S Emmrich; J E Katsman-Kuipers; K Henke; M E Khatib; R Jammal; F Engeland; F Dasci; C M Zwaan; M L den Boer; L Verboon; J Stary; A Baruchel; V de Haas; A A Danen-van Oorschot; M Fornerod; R Pieters; D Reinhardt; J H Klusmann; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

9.  Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.

Authors:  Mahban Irandoust; Julian Alvarez Zarate; Isabelle Hubeek; Ellen M van Beek; Karin Schornagel; Aart J F Broekhuizen; Mercan Akyuz; Arjan A van de Loosdrecht; Ruud Delwel; Peter J Valk; Edwin Sonneveld; Pamela Kearns; Ursula Creutzig; Dirk Reinhardt; Eveline S J M de Bont; Eva A Coenen; Marry M van den Heuvel-Eibrink; C Michel Zwaan; Gertjan J L Kaspers; Jacqueline Cloos; Timo K van den Berg
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

10.  In vitro anthracycline cross-resistance pattern in childhood acute lymphoblastic leukaemia.

Authors:  E Klumper; R Pieters; M L den Boer; D R Huismans; A H Loonen; A J Veerman
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.